Skip to main content
SpringerLink
Log in

Coagulation and fibrinolysis abnormalities in obesity

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Abnormalities in coagulation and haemostasis represent a well-known link between obesity and thrombosis (both arterial and venous). Several studies have shown that obese patients have higher plasma concentrations of all pro-thrombotic factors (fibrinogen, vonWillebrand factor (vWF), and factor VII), as compared to non-obese controls, with a positive association with central fat. Similarly, plasma concentrations of plasminogen activator inhibitor-1 (PAI-1) have been shown to be higher in obese patients as compared to non-obese controls and to be directly correlated with visceral fat. Furthermore, obesity is characterized by higher plasma concentrations of anti-thrombotic factors, such as tissue-type plasminogen activator (t-PA) and protein C, as compared to non-obese controls, the increase in these factors being likely to represent a protective response partly counteracting the increase in pro-thrombotic factors. The issue of whether adipose tissue contributes directly to plasma PAI-1, its products stimulating other cells to produce PAI-1, or whether it primarily contributes indirectly has not yet been resolved. It has been proposed that the secretion of interleukin-6 (IL-6) by adipose tissue, combined with the actions of adipose tissue-expressed TNF-α in obesity, could underlie the association of insulin resistance with endothelial dysfunction, coagulopathy, and coronary heart disease. The role of leptin in impairing haemostasis and promoting thrombosis has been recently reported. Finally, some hormonal abnormalities (androgen, F, catecholamines) associated with the accumulation of body fat may contribute to the impairment of coagulative pathway in obesity. As to intervention strategies, dietary (i.e., low-fat high-fiber diet) and lifestyle (i.e., physical activity) measures have been demonstrated to be effective in improving the obesity-associated pro-thrombotic risk profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Despres J.P. Health consequences of visceral obesity. Ann. Med., 2001, 33: 534–541.

    Article  CAS  PubMed  Google Scholar 

  2. De Pergola G., De Mitrio V., Giorgino F. et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int. J. Obes. Relat. Metab. Disord. 1997, 21: 527–535.

    Article  PubMed  Google Scholar 

  3. De Pergola G., De Mitrio V., Sciaraffia M. et al. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 1997, 46: 1287–1293.

    Article  PubMed  Google Scholar 

  4. Cigolini M., Targher G., Bergamo Andreis I.A., Tonoli M., Agostino G., De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler. Thromb. Vasc. Biol. 1996, 16: 368–374.

    Article  CAS  PubMed  Google Scholar 

  5. Sakkinen P.A., Wahl P., Cushman M., Lewis M.R., Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol. 2000, 152: 897–907.

    Article  CAS  PubMed  Google Scholar 

  6. Kario K., Matsuo T., Kobayashi H., Matsuo M., Sakata T., Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler. Thromb. Vasc. Biol. 1995, 15: 1114–1120.

    Article  CAS  PubMed  Google Scholar 

  7. Gallistl S., Sudi K.M., Borkenstein M., Weinhandl G., Zotter H., Muntean W. Correlation between cholesterol, soluble P-selectin, and D-dimer in obese children and adolescents. Blood Coagul. Fibrinolysis 2000, 11: 755–760.

    Article  CAS  PubMed  Google Scholar 

  8. Hong Y., Pedersen N.L., Egberg N., de Faire U. Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor- 1, triglycerides, and body mass index. Arterioscler. Thromb. Vasc. Biol. 1997, 17: 2776–2782.

    Article  CAS  PubMed  Google Scholar 

  9. Sartori M.T., Vettor R., De Pergola G. et al. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance. Thromb. Haemost. 2001, 86: 1161–1169.

    CAS  PubMed  Google Scholar 

  10. Vambergue A., Rugeri L., Gaveriaux V. et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb. Res. 2001, 101: 367–375.

    Article  CAS  PubMed  Google Scholar 

  11. Lowe GD, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables. Thromb. Haemost. 1999, 81: 918–924.

    CAS  PubMed  Google Scholar 

  12. Pannacciulli N., De Mitrio V., Sciaraffia M., Giorgino R., De Pergola G. A family history of type 2 diabetes is associated with lower sensitivity to activated protein C in overweight and obese premenopausal women. Thromb. Haemost. 2001, 86: 1593–1594.

    CAS  PubMed  Google Scholar 

  13. Mavri A., Alessi M.C., Bastelica D. et al. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001, 44: 2025–2031.

    Article  CAS  PubMed  Google Scholar 

  14. Alessi M.C., Morange P., Juhan-Vague I. Fat cell function and fibrinolysis. Horm. Metab. Res. 2000, 32: 504–508.

    Article  CAS  PubMed  Google Scholar 

  15. Eriksson P., Van Harmelen V., Hoffstedt J. et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb. Haemost. 2000, 83: 545–548.

    CAS  PubMed  Google Scholar 

  16. Loskutoff D.J., Fujisawa K., Samad F. The fat mouse. A powerful genetic model to study hemostatic gene expression in obesity/NIDDM. Ann. N.Y. Acad. Sci. 2000, 902: 272–282.

    Article  CAS  PubMed  Google Scholar 

  17. Seki T., Miyasu T., Noguchi T. et al. Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. J. Cell. Physiol. 2001, 189: 72–78.

    Article  CAS  PubMed  Google Scholar 

  18. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000, 49: 633–639.

    Article  CAS  PubMed  Google Scholar 

  19. Nordt T.K., Bode C., Sobel B.E. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor type I by proinsulin. Diabetologia 2001, 44: 1121–1124.

    Article  CAS  PubMed  Google Scholar 

  20. Samad F., Pandey M., Bell P.A., Loskutoff D.J. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol. Med. 2000, 6: 680–692.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Yudkin J.S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999, 22: C25–C30.

    Article  PubMed  Google Scholar 

  22. Westerbacka J., Yki-Järvinen H., Turpeinen A. et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler. Thromb. Vasc. Biol. 2002, 22: 167–172.

    Article  CAS  PubMed  Google Scholar 

  23. Chan P., Huang T.Y., Shieh S.M., Lin T.S., Tsai C.W. Thrombophilia in patients with hypertriglyceridemia. J. Thromb. Thrombolysis 1997, 4: 425–429.

    Article  PubMed  Google Scholar 

  24. He G., Pedersen S.B., Bruun J.M., Richelsen B. Regulation of plasminogen activitor inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and estrogen. Horm. Metab. Res. 2000, 32: 515–520.

    Article  CAS  PubMed  Google Scholar 

  25. Skurk T., Lee Y.M., Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001, 37: 1336–1340.

    Article  CAS  PubMed  Google Scholar 

  26. Halleux C.M., Declerck P.J., Tran S.L., Detry R., Brichard S.M. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J. Clin. Endocrinol. Metab. 1999, 84: 4097–4105.

    CAS  PubMed  Google Scholar 

  27. De Pergola G., De Mitrio V., Perricci A. et al. Influence of free testosterone on antigen levels of plasminogen activator inhibitor-1 in premenopausal women with central obesity. Metabolism 1992, 41: 131–134.

    Article  PubMed  Google Scholar 

  28. Kostantinides S., Schafer K., Loskutoff D.J. The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity. Ann. N.Y. Acad. Sci. 2001, 947: 134–141.

    Article  Google Scholar 

  29. Maruyama I., Nakata M., Yamaji K. Effect of leptin. Obesity and arterial thrombosis. Ann. N.Y. Acad. Sci. 2000, 902: 315–319.

    Article  CAS  PubMed  Google Scholar 

  30. Ozata M., Avcu F., Durmus O., Yilmaz I., Ozdemir I.C., Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes. Res. 2001, 9: 627–630.

    Article  CAS  PubMed  Google Scholar 

  31. De Mitrio V., De Pergola G., Vettor R. et al. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women. Metabolism 1999, 48: 960–964.

    Article  PubMed  Google Scholar 

  32. Morange P.E., Lijnen H.R., Alessi M.C., Kopp F., Collen D., Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler. Thromb. Vasc. Biol. 2000, 20: 1150–1154.

    Article  CAS  PubMed  Google Scholar 

  33. Morange P.E., Bastelica D., Bonzi M.F. et al. Influence of t- PA and u-PA on adipose tissue development in a murine model of diet-induced obesity. Thromb. Haemost. 2001, 87: 306–310.

    Google Scholar 

  34. Gallistl S., Sudi K.M., Cvirn G., Muntean W., Borkenstein M. Effects of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents. Int. J. Obes. Relat. Metab. Disord. 2001, 25: 529–532.

    Article  CAS  PubMed  Google Scholar 

  35. Bastard J.P., Vidal H., Jardel C. et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor- 1 gene during very low calorie diet in obese subjects. Int. J. Obes. Relat. Metab. Disord. 2000, 24: 70–74.

    Article  CAS  PubMed  Google Scholar 

  36. Marckmann P. Dietary treatment of thrombogenic disorders related to the metabolic syndrome. Br. J. Nutr. 2000, 83 (Suppl.): S121–S126.

    CAS  PubMed  Google Scholar 

  37. Yosefy C., Viskoper J.R., Laszt A. et al. The effect of fish oil on hypertension, plasma lipids, and hemostasis in hypertensive, obese, dyslipidemic patients with and without diabetes mellitus. Prostaglandins Leukot. Essent. Fatty Acids 1999, 61: 83–87.

    Article  CAS  Google Scholar 

  38. Charles M.A., Morange P., Eschwege E., Andre P., Vague P., Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the prevention of the risk of obesity. Diabetes Care 1998, 21: 1967–1972.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Emergency and Organ Transplantation (D.E.T.O.), Section of Internal Medicine, Endocrinology and Metabolic Diseases, University of Bari, Bari, Italy, Piazza Giulio Cesare 11, 70124

    Giovanni De Pergola & N. Pannacciulli

Authors
  1. Giovanni De Pergola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Pannacciulli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni De Pergola.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Pergola, G., Pannacciulli, N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25, 899–904 (2002). https://doi.org/10.1007/BF03344054

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344054

Key-words

Search

Navigation